2. Academic Validation
  3. Circulating Glioma Model for Chimeric Antigen Receptor T-Cell Therapy Investigations

Circulating Glioma Model for Chimeric Antigen Receptor T-Cell Therapy Investigations

  • J Vis Exp. 2025 Oct 17:(224). doi: 10.3791/68881.
Yuhan Zhang # 1,  Shuo Sun # 2,  Hongyi Liu 3,  Yun Chen 4,  Xiaoqin Chen 5
Affiliations

Affiliations

  • 1 School of Chemistry and Chemical Engineering, Southeast University; Department of Immunology, Key Laboratory of Human Functional Genomics of Jiangsu Province, Gusu School, Nanjing Medical University.
  • 2 Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University.
  • 3 Department of Neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University.
  • 4 School of Chemistry and Chemical Engineering, Southeast University; Department of Immunology, Key Laboratory of Human Functional Genomics of Jiangsu Province, Gusu School, Nanjing Medical University; [email protected].
  • 5 Department of Clinical Laboratory Medicine, Children's Hospital of Nanjing Medical University; [email protected].
  • # Contributed equally.
PMID: 41182951 DOI: 10.3791/68881
Abstract

Circulating tumor cells in cerebrospinal fluid (CSF) are a significant factor in tumor recurrence and intracranial metastasis in glioma. Many studies are attempting to identify effective strategies to target and eliminate the circulating tumor in CSF. Chimeric antigen receptor (CAR) T-cell therapy has been frequently used for various circulating tumors. However, research is limited due to the lack of a suitable circulating glioma model. Here, a circulating glioma model was developed and applied in CAR T-cell therapy investigations. This model was constructed using the lateral ventricle injection, which is widely used in the local treatment of intracranial disease. The glioma cells were injected into the lateral ventricle to form the intracranial primary tumor. The tumors that were shed from the lateral ventricle were used to indicate the circulating tumor in CSF. The model is easy to build and can be applied in various studies on the CAR T-cell therapy of circulating glioma. As a result, the circulating glioma model provides a unique glioma metastasis model for effective CAR T-cell therapy studies of the circulating tumor.

Figures
Products